SubHero Banner

Ezallor (rosuvastatin) – New drug approval

December 18, 2018 - The FDA approved Sun Pharmaceutical’s Ezallor (rosuvastatin) capsules, as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia or primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia); and as adjunctive therapy to other lipid-lowering treatments (eg, low-density lipoprotein [LDL] apheresis) or alone if such treatments are unavailable to reduce LDL-cholesterol, total cholesterol, and apolipoprotein B in adult patients with homozygous familial hypercholesterolemia.

Download PDF